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Abstract MicroRNAs are about 22 nucleotide long sin-
gle-stranded RNA molecules, negatively regulating gene
expression of a single gene or a gene network. In neural
tissues, they have been implicated in developmental and
neuroplasticity-related processes, such as neurogenesis,
differentiation, apoptosis and long-term potentiation. Their
molecular mode of action is reminiscent of findings of
genome-wide association studies in mental disorders,
unable to attribute the risk of disease to a specific gene, but
rather to multiple genes, gene-networks and gene-envi-
ronment interaction. As such, microRNAs are an attractive
target for research. Here, we review clinical studies con-
ducted in humans on microRNAs in mental disorders with
a particular focus on schizophrenia, bipolar disorder, major
depressive disorder and anxiety disorders. The majority of
clinical studies have focused on schizophrenia. The most
robust finding has been reported for rs1625579 located in
MIR137HG, which was associated with schizophrenia on a
genome-wide level. Concerning bipolar disorder, major
depression and anxiety disorders, promising results have
been published, but only a considerably smaller number of
clinical studies is available and genome-wide association
studies did not suggest a direct link to microRNAs so far.
Expression of microRNAs as biomarkers of mental disor-
ders and treatment response is currently emerging with
preliminary results. Larger-scaled genetic and functional
studies along with translational research are needed to
enhance our understanding of microRNAs in mental dis-
orders. These studies will aid in disentangling the complex
genetic nature of these disorders and possibly contribute to
the development of novel, individualized diagnostic and
therapeutic approaches.
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Introduction
The pathogenesis of mental disorders is a field of highly
active research, and many aspects remain elusive. The
molecular roles of microRNAs represent intriguing mech-
anisms, which may unify some aspects of competing dis-
ease models. Discovered more than 20 years ago (Lee et al.
1993), mature microRNAs are small, about 22 nucleotide
long single-stranded RNA molecules, which canonically
lead to downregulation of gene expression upon interfer-
ence with the 30-untranslated region (UTR) of one or sev-
eral target mRNAs, thereby regulating gene networks
(Bartel and Chen 2004). MicroRNAs are located within
hostgenes (intronic protein coding, intronic non-protein
coding or exonic non-protein coding) or located intergenic
and about 50 % of microRNAs are found in clusters (Kim
and Nam 2006). Genomic analysis has revealed that the
density of polymorphisms within microRNA genes is low,
emphasizing their master regulatory role (Han and Zheng
2013). However, genetic variation in microRNA-binding
sites may cause expression of many genes to differ, further
supporting a key regulatory role for microRNAs (Kim and
Bartel 2009).
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Several proteins are involved in the biogenesis and
molecular action of microRNAs (Bartel 2004), and six
major steps, summarized in Fig. 1, have been outlined:
(I) RNA polymerase II transcribes double-stranded hairpin
structures of up to 1,000 nucleotides length (primary (pri-
)microRNA), which are (II) cleaved by a complex con-
taining the endonuclease Drosha and the Drosha/DiGeorge
syndrome critical region 8 (DGCR8) to about 100 nucle-
otide long microRNA precursors/stem loops (pre-microR-
NA). The precursors are (III) exported from the nucleus by
two proteins, Exportin5 and Ras-related nuclear protein
(RanGTP). In the cytoplasm they are (IV) further processed
by the protein Dicer and its cofactor Tar RNA-binding
protein (TRBP) to microRNA duplexes by cleaving the
loop and finally (V) to single, mature microRNA strands
upon disruption of the duplex by the protein Helicase. One
or both strands are loaded (VI) onto the Argonaute
homologue protein Ago2, leading to the formation of the
RNA-induced silencing complex (RISC) in combination
with a target mRNA.
Genes encoding microRNAs are named using the three-
letter prefix ‘‘mir’’ with an identifying number (e.g. MIR22
in Homo sapiens, Mir22 in Mus musculus). To refer to a
non-protein-coding hostgene of a given microRNA, the
extension ‘‘HG’’ may be used (e.g. MIR22HG). Orthologs
share the same number, regardless of organism, paralogs
are distinguished by a lettered suffix and distinct genomic
loci yielding identical mature microRNA sequences are
indicated by numerical suffixes (e.g. MIR15B, Mir15b or
MIR16-1). The name of a mature microRNA sequence
contains at least three parts: (I) a prefix indicating the
species in combination with (II) the prefix ‘‘miR’’ and (III)
the number as used for the microRNA gene, all divided by
a hyphen. If two mature sequences, derived from the 50-
and 30-arm of the hairpin-structured precursor-microRNA
(see below) have been identified, (IV) the suffixes ‘‘-5p’’ or
‘‘-3p’’ are used to indicate the strand (e.g. hsa-miR-22-3p
in Homo sapiens or mmu-miR-15b-5p in Mus musculus).
When referring to microRNA hairpin precursor sequences
or microRNA gene families, the species-indicating prefix is
omitted and the prefix ‘‘miR’’ is written in lowercase (e.g.
miR-22). Nomenclature of microRNAs has been addressed
in detail elsewhere (Ambros et al. 2003; Griffiths-Jones
et al. 2006; Kozomara and Griffiths-Jones 2014).
In mammals, microRNAs work by imperfect base-
pairing with the target mRNA (Ambros 2004). The ‘‘seed
sequence’’ of the mature microRNA, involving at least
nucleotides 2–7, canonically forms perfect base-pairing
with the mRNA, being a crucial, but not the exclusive
determinator of the stability of microRNA: mRNA inter-
action (Grimson et al. 2007). Several bioinformatic algo-
rithms have been developed for the prediction of
microRNA:mRNA interaction (Sethupathy et al. 2006; Mu
and Zhang 2012; Peterson et al. 2014) and more than 60 %
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of human genes may be regulated by microRNAs (Fried-
man et al. 2009). However, most of these predictions still
warrant experimental validation, since the complex mech-
anisms of microRNA:mRNA interaction result in a high
false positive rate of these predictions (Kertesz et al. 2007),
confounding pathway analyses.
Since their initial discovery in 1993, 1,881 human
microRNA loci have been annotated in miRBase 21,
leading to more than 2,500 mature microRNA transcripts
(Kozomara and Griffiths-Jones 2014). Contrary to the
protein level, only a fraction of microRNAs and target
sequences are conserved between species, which leaves
many annotated human microRNAs waiting for their
functional characterization. A plethora of interactions and
regulations is possible, as one can estimate that on average
more than 20 microRNAs may regulate a single target gene
(Arnold et al. 2012). MicroRNA expression and function
thus depend on tissue, cell-type and developmental stage-
specific expression patterns (Bartel and Chen 2004;
Landgraf et al. 2007; Ziats and Rennert 2014). The inter-
play between transcription factors, gene networks and
microRNAs may therefore become very intricate, as par-
adigmatically illustrated by two microRNAs acting in a
double-negative feedback loop to control neuronal cell fate
(Johnston et al. 2005).
About 75 % of annotated microRNAs were detected in
human brain with regional and developmental specificity
(Shao et al. 2010; Hu et al. 2011; Boudreau et al. 2014;
Ziats and Rennert 2014). MicroRNAs have been implicated
in the regulation of basic neuronal processes in develop-
ment, differentiation and synaptic plasticity, as reviewed
(Kosik 2006; Schratt 2009a, b; Im and Kenny 2012;
McNeill and Van Vactor 2012; Serafini et al. 2012; Sun
et al. 2013). Some examples may be given: miR-124 is
expressed in post-mitotic neurons and involved in (I) adult
neurogenesis in the subventricular zone stem cell niche by
targeting Sox9, thereby allowing neuronal differentiation
(Cheng et al. 2009), (II) in regulating synaptic plasticity
through CREB (Rajasethupathy et al. 2009) and (III) in
mediating neural progenitor mitotic exit and dendritic
morphogenesis by targeting Baf53a in combination with
miR-9 (Yoo et al. 2009). MiR-134 is localized in the
synapto-dendritic compartment and negatively regulates
the size of dendritic spines (Schratt et al. 2006). Mir-138 is
highly enriched in the brain, localized within dendrites and
negatively regulates the size of dendritic spines by con-
trolling the expression of Apt1, an enzyme regulating
palmitoylation status of proteins such as the Ga13 subunit
of G proteins (Siegel et al. 2009).
MicroRNAs in human diseases have been largely
investigated in cancer (Ryan et al. 2010) and cardiovas-
cular disorders (Thum et al. 2007), but are also involved in
autoimmune diseases (Sayed and Abdellatif 2011) and in
neurodegenerative disorders (Van den Hove et al. 2014).
Regulatory genetic variations affecting microRNA activity
has thus become an emerging field of research. Chromo-
somal alterations, epigenetic modification, polymorphic
promoter elements and polymorphism within microRNAs
(cis factors), as well as mutations in genes of proteins
involved in microRNA processing and in the target site
itself (trans factors) have been described (Sethupathy and
Collins 2008).
Here, we review clinical studies on microRNAs in
mental disorders and summarize data on the potential use
of microRNAs as biomarkers. We searched Medline using
the following search string and yielded 895 results (Octo-
ber 2014): ‘‘(microRNA OR miRNA OR miR) AND
(Schizophrenia OR SCZ OR psychosis OR bipolar disorder
OR BPD OR depression OR depressive OR depress* OR
affective OR MDD OR anxiety OR panic OR agoraphobia
OR trait OR psychiatry OR psychiatric)’’. To focus the
review on human data of schizophrenia, bipolar disorder,
major depressive disorder and anxiety disorders, only
research articles related to humans, human tissue or human
cell lines in a clinical context were considered. We delib-
erately opted for this limitation of our review to evaluate
the contribution of microRNAs to clinical heterogeneity
and individuality in terms of phenotypic variance and
treatment response. We complemented our literature search
by reviewing the references of included articles. Taken
together, 112 publications remained for primary review.
Schizophrenia
Genetic studies
Early association studies on single nucleotide polymor-
phisms (SNPs) related to microRNA reported an associa-
tion for MIR206 (rs17578796) in a Scandinavian (Hansen
et al. 2007) and for MIR30E (rs112439044) in a Han
Chinese (Xu et al. 2010a) sample of patients with schizo-
phrenia (SCZ). A recent study replicated the finding
regarding MIR30E in a Japanese sample (Watanabe et al.
2013). Negative findings were published for MIR130B
(rs861843), which was investigated due to its localization
within the risk locus for SCZ on chromosome 22q11 in a
Russian sample (Burmistrova et al. 2007), MIR146A and
MIR499 in a Chinese sample (Zou et al. 2012) and for
MIR185, which is located closely to MIR130B and deleted
in the 1.5 megabase 22q11.2 microdeletion associated with
SCZ, in the sample of the Psychiatric Genomics Consor-
tium and a German sample (Forstner et al. 2014).
Concerning individual risk induced by rare variants, an
investigation of microRNA genes on the X-chromosome
identified 8 ultra-rare variants in the precursor or mature
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microRNA sequence (let-7f-2, miR-18b, miR-188, miR-
325, miR-502, miR-505, miR-509-3, miR-510, miR-660)
in 8 of 192 American males suffering from SCZ, which
were not found in a large and diverse control sample (Feng
et al. 2009). A recent study reported an enrichment of rare
copy number variations (CNVs) overlapping with mi-
croRNAs in SCZ with 25 microRNAs implicated by rare
CNVs in two or more unrelated subjects (Warnica et al.
2014). Most of these microRNAs are presently uncharac-
terized and pathway analysis suggested a functional
enrichment of microRNA targets in neurodevelopmental
processes, including axonogenesis and neuron projection.
Due to the high false positive rate of prediction algorithms,
data warrant experimental confirmation.
Several investigations have studied polymorphic micr-
oRNA-binding sites in target genes related to SCZ.
Focusing on quantifiable phenotypes of SCZ, a German
case–control sample reported a polymorphism in the
30UTR of CPLX2 (rs3822674) to be associated with cog-
nition and to interfere with repression of CPLX2 expression
by hsa-miR-498 (Begemann et al. 2010). Binding of mi-
croRNAs to polymorphic sites in the 30UTR of the BDNF
gene was investigated in a study confirming two SNPs
involved in hsa-miR-26a-5p and hsa-miR-26b-5p binding
(rs11030100 and rs11030099), yet both SNPs were not
found to be associated with SCZ in an Italian sample
(Caputo et al. 2011). Previously, a decreased expression of
the BDNF targeting microRNA hsa-miR-195-5p was
reported in postmortem prefrontal cortex samples of SCZ
cases (Mellios et al. 2009), but genetic variation was not
tested. A SNP in the 30UTR of DRD2 (rs1130354) was
reported to interfere with hsa-miR-326-mediated repression
of DRD2 expression, yet failed to be associated with SCZ
in an American sample (Shi et al. 2014). Another study
focused on rs11122396 in the 30UTR of DISC1 and
reported hsa-miR-135b-5p to interfere with DISC1
expression for the major (A), but not for the minor
(G) allele (Rossi et al. 2014). Yet association of
rs11122396 with SCZ or its symptoms was not tested,
leaving room for further investigations.
Applying a different methodological approach, SNPs in
the 30UTR of SCZ candidate genes were analyzed for free
energy of microRNA binding in silico. Two SNPs previ-
ously reported to be associated with SCZ were experi-
mentally identified to interfere with hsa-miR-124-3p-
mediated repression of RGS4 expression (rs10759) and
hsa-miR-138-5p-mediated repression of COMT expression
(rs165599). The same study also suggested a previously
unreported SNP (rs3219151) in the 30UTR of GABRA6 to
be associated with SCZ in a Han Chinese sample (Gong
et al. 2013), but interference with microRNA binding was
not experimentally studied. Hsa-miR-138-5p was recently
also reported to be a potential regulator of memory
performance in humans (Schröder et al. 2014). This study
combined GWAS data on 13 traits of episodic and working
memory performance of a German sample aged older than
60 years (n = 1318) with molecular studies. A SNP
upstream of MIR138-1 (rs9882688) modulated expression
of hsa-miR-138-5p and was among the three top hits of the
GWAS on memory performance. Previous molecular
studies had suggested important roles of miR-138 in spine
morphogenesis and miR-124 in neuronal fate, as explained
in the introduction and reviewed (Sun et al. 2013).
Two studies have focused on microRNA processing, and
both were conducted in Han Chinese case–control samples.
Analysis of 967 SNPs within 59 microRNA processing
genes suggested an intronic SNP in EIF4ENIF1
(rs7289941) to be associated with SCZ (Zhang et al. 2012).
A second, smaller-sized investigation reported rs3757 in
DGCR8 as well as rs3742330 in DICER to be associated
with SCZ (Zhou et al. 2013). The influence of these SNPs
on microRNA processing has not been experimentally
evaluated.
Several investigations have focused on a polymor-
phism in the hostgene of hsa-miR-137 (rs1625579), with
genome-wide significance in genome-wide association
studies (GWAS) of SCZ so far (The Schizophrenia Psy-
chiatric Genome-Wide Association Study (GWAS) Con-
sortium 2011; Cross-Disorder Group of the Psychiatric
Genomics Consortium 2013a; Ripke et al. 2013). The
SNP is located 8,692 bp downstream of MIR137. It should
be noted, that MIR137HG also codes for MIR2682, which
is located only 7,864 bp downstream of rs1625579 and
presently uncharacterized. Four replication studies were
published so far, all conducted in Han Chinese case–
control samples. Among 33 SNPs spanning MIR137HG
and the hsa-miR-137 target CACNA1C, a nominally sig-
nificant association with SCZ was reported for rs1625579
(MIR137HG) and both rs1006737 and rs4765905 in
CACNA1C (Guan et al. 2014). More recently, rs1625579
was associated with SCZ and working memory perfor-
mance of SCZ patients as tested by Brief Assessment of
Cognitions in Schizophrenia (Ma et al. 2014). However,
no association was found in two case–control samples, yet
the samples sizes were not adequatly powered to reliably
detect an association, given the GWAS-reported odds
ratio between 1.07 and 1.19 (Wang et al. 2014a; Yuan
et al. 2014).
A recent, smaller sized, European–Australian GWAS of
psychosis phenotypes (schizophrenia, schizoaffective dis-
order, psychotic bipolar disorder) tagged rs1625579 by
rs1782810, which is located 594 bp downstream of
rs1625579 in an intron of MIR137HG, yet only a trend
towards nominal association was reported, possibly due to
limited power of this study (Psychosis Endophenotypes
International Consortium et al. 2014).
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Sequencing of MIR137HG revealed (I) four sequence
variations, yet contributing no SCZ risk in a Japanese case–
control sample (Egawa et al. 2013), and (II) two rare
variants in a northern Swedish case–control sample, lead-
ing to reduced hsa-miR-137 expression in heterologous
expression systems (Strazisar et al. 2014). Both cases and
controls showed a trend towards decreased expression of
hsa-miR-137 for the TT risk genotype of rs1625579 in
postmortem prefrontal cortex (Guella et al. 2013).
On a molecular level, hsa-miR-137 was reported to
regulate several SCZ candidates such as CACNA1C,
CSMD1, C10orf26 and TCF4 (Kwon et al. 2013), as well
as ZNF804A (Kim et al. 2012) and the autism candidate
RORA (Devanna and Vernes 2014) using luciferase
reporter assays. Also, a rare variable number tandem repeat
(VNTR) polymorphism at the 50 end of the hsa-miR-137
precursor was reported to reduce hsa-miR-137 expression
for 9 and 13 VNTR alleles, yet the association to SCZ
needs to be determined (Mamdani et al. 2013). Interest-
ingly, DRD2 and COMT expression may be indirectly
regulated via the hsa-miR-137 target ZNF804A, providing
a link to the dopamine hypothesis of schizophrenia (Gir-
genti et al. 2012). Translational studies had previously
suggested an important role of miR-137 in modulating
differentiation of adult neuronal stem cells by repressing
Ezh2 (Szulwach et al. 2010), differentiation of embryonic
stem cells by targeting Lsd1 (Sun et al. 2011) as well as
neuronal maturation and dendritic spine morphogenesis by
interference with Mib1 (Smrt et al. 2010). Two recent
reviews focus on these findings and its possible impact on
SCZ (Wright et al. 2013; Yin et al. 2014).
On a functional level, several studies have investigated
rs1625579. The amplitude of the P300 auditory event-
related potential and the N100 amplitude of the ‘‘odd-ball’’
paradigm were nominally associated with rs1625579 in a
Belgian SCZ patient sample (Decoster et al. 2012) and a
European ancestry case–control sample for bipolar disorder
(BPD) and SCZ (Hall et al. 2014). The rs1625579 TT risk
genotype was reported to confer subtle changes in terms of
fewer, rather mood-congruent psychotic symptoms,
reduced episodic memory and attentional control in an Irish
SCZ sample (Cummings et al. 2013). An Australian SCZ
sample reported no association of rs1625579 with cognitive
deficits, but prediction of impaired cognitive performance
using rs1625579 gentoype in combination with negative
symptoms (Green et al. 2013).
On a neuronal network level, a fMRI study in healthy
Scottish individuals at genetic risk for SCZ or BPD due to
one first-degree or two second-degree affected relatives
revealed reduced brain activation across several regions for
the TT risk genotype using the Hayling sentence comple-
tion paradigm (Whalley et al. 2012). The TT risk genotype
was associated with dorsolateral prefrontal cortex
hyperactivation (considered to be a measure of insufficient
cortical control) in SCZ patients using the Sternberg Item
Response Paradigm, but not with lower working memory
performance and longer response times (van Erp et al.
2014). Two studies have focused on healthy individuals.
The TT risk genotype showed increased functional con-
nectivity between right amygdala and frontal regions
involved in emotional processing in a healthy Irish sample
using a face-processing task (Mothersill et al. 2014).
Dorsolateral prefrontal-hippocampal functional connectiv-
ity was suggested to depend on the rs1625579 genotype
and to correlate with working memory performance in
healthy Han Chinese individuals by resting state fMRI (Liu
et al. 2014).
Structural MRI studies yielded contradictory results: an
initial case–control study reported reduced hippocampal
and increased lateral ventricle volume for SCZ patients
being carriers of the TT risk genotype (Lett et al. 2013),
which was not replicated in a recent study of multiple brain
structures in a larger number of SCZ patients (Rose et al.
2014). Four studies in healthy individuals reported no
association of rs1625579 with brain volume. No impact of
rs1625579 on the variability of white matter structure was
observed using diffusion tensor imaging (DTI) in healthy
Irish participants (Kelly et al. 2014). Two samples (Han
Chinese and European) previously used for analysis of
genetic effects on brain volume in healthy individuals (Li
et al. 2012; Stein et al. 2012) yielded no significant asso-
ciation with rs1625579 using MRI (Li and Su 2013).
Likewise, a study investigating SNPs within MIR137HG,
TCF4 and ZNF804A in relation to the brain structure of
1,300 healthy adults reported no effect on total brain vol-
ume, gray matter, white matter or hippocampal volume
using volumetry and voxel-based morphometry (Cousijn
et al. 2014). Given the large sample size of this study,
rs1625579 exerts most likely only a very small effect on
brain volume in healthy adults.
Taken together, while rs1625579 represents a genome-
wide risk variant for SCZ, available evidence points
towards only a modest impact on phenotypic variance of
SCZ (see Table 1 for summary). Yet, larger functional
studies are needed to fully assess rs1625579 in SCZ.
Expression studies
Most studies on microRNA expression in SCZ have
investigated postmortem brain samples and focused on the
prefrontal cortex. More recent studies address microRNA
expression as a potential biomarker of SCZ and a predictor
of treatment response using peripheral tissue or blood
serum samples.
Studies focusing on postmortem brain expression in
SCZ yielded heterogeneous results so far, with reports of
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increased microRNA expression (Beveridge et al. 2008,
2010; Kim et al. 2010; Santarelli et al. 2011; Wong et al.
2013) or decreased microRNA expression (Perkins et al.
2007; Mellios et al. 2009; Zhu et al. 2009; Moreau et al.
2011; Miller et al. 2012; Scarr et al. 2013; Guella et al.
2013), gender-specific effects (Mellios et al. 2012) or no
effects at all (Burmistrova et al. 2007). These studies differ
in several factors such as the sample size, the number of
investigated microRNAs as well as the method applied for
microRNA isolation and detection. Robust replication of
any of these results has not been published so far. Results
and methodological issues have been reviewed in greater
detail elsewhere (Kolshus et al. 2013; Maffioletti et al.
2014).
One study focused on exosomes, which are cellular
secretory vesicles containing microRNAs in neuronal tis-
sue isolated from postmortem prefrontal cortex and sug-
gested an increase in microRNA expression in mental
disorders, with hsa-miR-497-5p significantly upregulated
in SCZ and hsa-miR-29c-3p in bipolar disorder (Banigan
et al. 2013).
Two recent studies have investigated the same individ-
uals from the Stanley Neuropathology Consortium, suf-
fering from SCZ, bipolar disorder (BPD) or major
depressive disorder (MDD) compared to healthy controls
(n = 15 each). The first study assessed expression of mi-
croRNAs in dorsolateral prefrontal cortex by high-
throughput quantitative real-time PCR and additionally
compared individuals grouped into those having completed
suicide and those having died from a natural death
(Smalheiser et al. 2014). For a subset of three patients and
six controls, next-generation sequencing of synaptosomes
was performed, thereby evaluating all annotated microR-
NAs and mRNA simultaneously, contrary to high-
throughput real-time PCR relying on preselected microR-
NA panels (typically 384 microRNAs). Synaptosomes may
reflect neuron-specific microRNA expression more ade-
quately than whole brain tissue samples (Lugli et al. 2012).
Most microRNAs were only modestly dysregulated, rarely
exceeding a factor of two, with reduced expression in SCZ.
Hsa-miR-219-5p (highly enriched in synaptosomes by a
factor of five) was most strongly downregulated by 70 % in
SCZ. The NMDA-receptor antagonist dizocilpine, which
induces schizophrenia-like behavioral deficits in mice, was
identified to downregulate miR-219 expression (Kocerha
et al. 2009). The pattern of microRNA dysregulation was
partially similar between SCZ and BPD, but both were
different from MDD or individuals having completed sui-
cide. These results correspond to reports on the genetic
architecture of major mental disorders, suggesting a partial
overlap between SCZ and BPD (Cross-Disorder Group of
the Psychiatric Genomics Consortium 2013a). Of note, hsa-
miR-508-3p showed reduced levels in SCZ, BPD and
MDD, yet no specific reports on miR-508 in a neuronal
context are available.
The second study performed transcriptome sequencing
of dentate gyrus cells isolated from postmortem brain by
laser capture microdissection and reported disrupted sig-
naling of hsa-miR-182-5p (Kohen et al. 2014). In healthy
controls and BPD patients, but not in SCZ and MDD
patients, expression of MIR182 depended on rs76481776.
Interestingly, a previous study reported rs76481776 to be
associated with late insomnia in major depression and to
modulate miR-182 expression, assessed in heterologous
expression systems (HeLa cells) using luciferase activity
assays, but not in brain tissue of MDD patients (Saus et al.
2010).
Peripheral tissue expression of microRNAs was studied
in several ways. 33 microRNAs were significantly, but only
modestly (not exceeding 0.75-fold) downregulated in SCZ,
with 17 microRNAs located within the DLK-DIO3 region
on chromosome 14q32 in peripheral mononuclear blood
cells of 112 Australian SCZ patients and 76 controls using
microarrays (Gardiner et al. 2012). Interestingly, hsa-miR-
134-5p was among the most robustly downregulated mi-
croRNAs. However, expression of hsa-miR-134-5p was
increased in postmortem prefrontal cortex samples of SCZ
(Santarelli et al. 2011) and molecular studies suggested
increased, not decreased miR-134 to lead to reduced syn-
aptic development, maturation or plasticity (Schratt et al.
2006).
Another study tested directly, whether microRNA
expression in white blood cells may serve as a valid bio-
marker of SCZ using a Taiwanese sample consisting of 30
cases and 30 controls applying high-throughput real-time
PCR (Lai et al. 2011). Seven microRNAs (hsa-miR-34a-
5p, hsa-miR-432-5p, hsa-miR-449a, hsa-miR-548d-3p,
hsa-miR-564, hsa-miR-572 and hsa-miR-652-3p) were
suggested to predict SCZ as well as its clinical symptoms
with low correlation coefficients. Dysregulation of hsa-
miR-34a-5p (Kim et al. 2010) and hsa-miR-652-3p) was
reported for postmortem prefrontal cortex samples of SCZ;
miR-432 and miR-572 were implicated in autism (Abu-
Elneel et al. 2008; Mundalil Vasu et al. 2014) and miR-449
in Alzheimer’s disease (Cogswell et al. 2008). A more
recent study aimed to investigate microRNA expression
directly in neural tissue. The olfactory neuroepithelium,
which is one of the few accessible neural tissues containing
neurons and stem cells, was evaluated in a small (18
patients and controls) American sample using high-
throughput real-time PCR. An increase of about twofold in
hsa-miR-382-5p, which could not be detected in lympho-
blastoid cell lines, as well as a decrease in hsa-miR-532-3p
and hsa-miR-660 expression in SCZ patients was reported
(Mor et al. 2013). Notably, the microRNA level of each
individual participant is illustrated, allowing to assess the
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large variance between individuals and highlighting an
important problem of microRNA expression studies. Pre-
vious reports suggested a rare mutation in MIR660 to be
associated with SCZ (Feng et al. 2009). Hsa-miR-532-5p,
but not -3p, was upregulated and hsa-miR-382-5p was
downregulated in postmortem dorsolateral prefrontal cor-
tex in SCZ (Santarelli et al. 2011). Translational studies
suggested miR-382 to be regulated in a MeCP2-dependent
fashion (Urdinguio et al. 2010) and to be involved in
alcohol addiction (Li et al. 2013a).
Whether microRNAs may serve as predictors of anti-
psychotic treatment response has been tested in three
studies. One study investigated serum levels of microRNAs
previously reported to be associated with SCZ pre- and
post-treatment with risperidone in a Han Chinese patient
sample. A decrease in hsa-miR-365a-3p and hsa-miR-
520c-3p serum levels compared to baseline was observed
after 1 year of treatment, but no correlation of expression
level with clinical symptoms was reported (Liu et al. 2013).
A second study suggested plasma levels of hsa-miR-346, a
microRNA located in the intron of the SCZ candidate
GRID1 (Zhu et al. 2009), to become dysregulated in
patients upon treatment with risperidone (Shi et al. 2012).
More recently, a naturalistic study, yet involving only 20
Han Chinese patients, observed a decrease in serum levels
of hsa-miR-181b-5p, a microRNA previously reported to
be upregulated in the prefrontal cortex in SCZ (Beveridge
et al. 2008), to correlate with successful antipsychotic
treatment after 6 weeks (Song et al. 2014).
Indirect evidence for microRNA was given by a tran-
scriptome study of lymphoblastoid cell lines derived from a
SCZ case–control sample using microarrays (Sanders et al.
2013). DICER1 was reported to be upregulated in SCZ, in
line with previous reports on postmortem prefrontal cortex
samples (Beveridge et al. 2010; Santarelli et al. 2011) and
genetic association studies (Zhou et al. 2013), potentially
leading to increased microRNA expression.
Taken together, while many results are promising and
appear to relate to each other, preselection of tested mi-
croRNAs, methodological issues and sample sizes sets
important limits to the interpretation of data. The variance
of detected microRNA expression levels between individ-
uals, the different methods applied in microRNA extrac-
tion, detection and normalization as well as the inherent
noise of high-throughput methods are the main limitations.
Bipolar disorder
Genetic studies
Studies on microRNA in bipolar disorder (BPD) have
mainly been conducted in the context of mixed SCZ and
BPD case–control studies, since a high genetic correlation
between SCZ and BPD has been described (Cross-Disorder
Group of the Psychiatric Genomics Consortium 2013b). In
a cross-disorder analysis of five major psychiatric disor-
ders, MIR137HG rs1625579 was not among the top hits of
BPD, contrary to SCZ and autism spectrum disorders
(Cross-Disorder Group of the Psychiatric Genomics Con-
sortium 2013a). Only one genetic study in a Han Chinese
case–control sample has focused on microRNAs in BPD
specifically, investigating a microRNA reported to regulate
BDNF expression. An epistatic effect of MIR206
(rs16882131) and BDNF (rs6255) concerning BPD-I sus-
ceptibility and treatment response was reported (Wang
et al. 2014b). In another study, a SNP in the 30UTR of
GRM7 (rs56173829) was associated with BPD (Kandasw-
amy et al. 2014). Bioinformatic analysis by PolymiRTS 3.0
(Bhattacharya et al. 2014) suggested this SNP to modulate
binding of several microRNAs, most likely hsa-miR-4295,
hsa-miR-130a-3p and hsa-miR-130b-3p. However, exper-
imental validation was not conducted. A previous study
had suggested lithium- and valproate-dependent regulation
of Grm7 by miR-34a in rat neuronal tissue (Zhou et al.
2009) However, rs56173829 was not predicted to modulate
binding of miR-34a and experimental evidence is missing.
Most importantly, a large-scale genome-wide associa-
tion study of BPD (ncases = 7,481, ncontrols = 9,250 in the
discovery sample and ncases = 4,496, ncontrols = 42,422 in
the replication sample) did not report variants directly
affecting microRNAs (Psychiatric GWAS Consortium
Bipolar Disorder Working Group 2011). However, a gen-
ome-wide significant association was reported for ODZ4,
which harbors MIR708 and MIR5579 in its first intron. Till
now, these results have not been taken up and investigated
in more detail. Functional studies on both microRNAs
focusing on their potential neurobiological role have not
yet been conducted.
Expression studies
Studies on gene expression in mixed SCZ/BPD and SCZ/
BPD/MDD studies have been mentioned in the context of
the review on SCZ (Banigan et al. 2013; Kohen et al. 2014;
Smalheiser et al. 2014).
Two studies have focused on microRNA levels in the
context of treatment with mood stabilizers in human tissue.
The first study was conducted in lymphoblastoid cell lines
from 10 BPD patients and 10 unaffected family members
to assess the impact of lithium on microRNA expression
(Chen et al. 2009). 13 microRNAs, previously suggested to
respond to lithium and valproate treatment in rodents were
assessed. Four microRNAs were dysregulated after 16 days
of treatment (hsa-miR-34a-5p, hsa-miR-152-3p, hsa-miR-
155-5p, hsa-miR-221-3p). The overall change of
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microRNA expression was small and no microRNA
reached a twofold change. Contrary to a previous report in
rat hippocampus, hsa-miR-34a-5p and hsa-miR-221-3p
were upregulated in humans upon lithium treatment. A
second study focused on hsa-miR-134-5p, which was pre-
viously reported to negatively regulate dendritic spine
volume and synapse formation (Schratt et al. 2006). A
decrease in hsa-miR-134-5p plasma levels was observed
during manic phases and correlated with symptom severity.
This decrease was reversed upon successful treatment with
different mood stabilizers (Rong et al. 2011). In SCZ, a
modest increase of hsa-miR-134-5p was reported in the
dorsolateral prefrontal cortex of postmortem samples
(Santarelli et al. 2011), putatively reflecting the molecular
function of miR-134 in terms of decreased synaptic plas-
ticity. The relevance of these three reports regarding the
etiology of the corresponding disorder needs to be further
explored. Moreover, these findings underscore the neces-
sity of several lines of evidence to draw a consistent con-
clusion on putative molecular disease processes and
evaluation of risk factors.
Indirect evidence was given by a study investigating
microRNA expression in blood monocytes during post-
partum psychosis. Downregulation of hsa-miR-146a-5p
during first time postpartum psychosis was reported. A
subgroup of 11 out of 20 postpartum psychosis patients,
having previously been diagnosed with bipolar disorder,
also showed downregulation of hsa-miR-212-3p and hsa-
miR-92a-3p (Weigelt et al. 2013). However, the small
sample size renders the results primarily hypothesis
generating.
Concerning a potential application of microRNAs as
biomarkers of BPD and treatment success, all these results
have to be considered preliminary.
Major depressive disorder
Genetic studies
Early genetic investigation of microRNAs in MDD repor-
ted a rare SNP in the precursor of MIR30E (rs112439044),
previously found in the context of SCZ (Xu et al. 2010a), to
be associated with MDD in a Han Chinese population (Xu
et al. 2010b). In an analysis of five microRNAs involved in
the circadian clock, a SNP in MIR182 (rs76481776) was
reported to be associated with late insomnia in MDD (Saus
et al. 2010). Another study reported rs1653625 in the
30UTR of P2RX7 to be associated with MDD in a Hun-
garian case–control sample. This SNP was predicted to
interfere with binding of several microRNAs, yet none
were experimentally tested (Rahman et al. 2010). In a
subsequent study of the same group, this finding could not
be replicated, while an association with the severity of
depression symptoms in BPD patients was reported (Hal-
mai et al. 2013). A recent study conducted genome-wide
DNA methylation profiling of neuronal and glial nuclei and
reported an additive genetic and epigenetic association of
rs7208505, located in the 30UTR of SKA2, with suicide
(Guintivano et al. 2014). Suicidal ideation was associated
with rs7208505. SKA2 gene expression was significantly
lower in those who died by suicide and was associated with
genetic and epigenetic variation of rs7208505. Hsa-miR-
301a-3p was previously reported to regulate expression of
SKA2 (Cao et al. 2010). MIR301A is located intronically
within SKA2 and upstream of rs7208505. In combination
with epigenetic variation (methylation) proximal to
MIR301A, 40 % of SKA2 gene expression could be
explained by this SNP.
Most importantly, a meta-analysis of GWAS data for
major depressive disorder did not report variants directly
related to microRNAs reaching genome-wide significance
or to be among the top hits (Major Depressive Disorder
Working Group of the Psychiatric GWAS Consortium
2013). Given the large sample size (ncases = 9,240, ncon-
trols = 9,519 in the discovery sample and ncases = 6,783,
ncontrols = 50,695 in the replication sample), this finding is
of major importance. However, four microRNA genes were
located in regions (±300 kb) showing a p value below
0.005 (MIR1224, MIR1471, MIR708, MIR30E and
MIR30C1), thereby providing modest further support for
MIR30E. However, due to specific statistical issues con-
cerning MDD (Flint and Kendler 2014), the study may not
have reached the same power as GWAS on SCZ.
Concerning genes involved in microRNA processing,
one study reported an increased risk for MDD driven by a
SNP (rs3757) in the 30UTR of the DGCR8 gene and a SNP
(rs636832) in AGO1 (He et al. 2012). Yet, interference
with microRNA binding was not experimentally
confirmed.
Taken together, present data suggest a smaller contri-
bution of microRNAs towards the risk for MDD compared
to SCZ. Functional studies or data on dimensional pheno-
types are presently not available.
Expression studies
Studies on mixed SCZ/BPD/MDD samples have been
mentioned in the context of SCZ (Kohen et al. 2014;
Smalheiser et al. 2014). MicroRNA expression in post-
mortem brain samples have reported a global downregu-
lation of microRNA expression in depressed suicide
completers (Smalheiser et al. 2012), but also an upregula-
tion of microRNAs (hsa-miR-139-5p, hsa-miR-320c and
hsa-miR-34c-5p), targeting two polyamine genes (SAT1
and SMOX), which have been observed to be
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downregulated in depressed suicide completers (Lopez
et al. 2014a). It should be noted, that the control groups
differed between those two studies, potentially explaining
the divergent findings, although the same brain bank was
used. A larger study reported the brain and primate-specific
hsa-miR-1202 to be downregulated in MDD. A target of
hsa-miR-1202 is the metabotropic glutamate receptor 4
(GRM4), previously implicated in anxiety-like behavior in
translational studies (Davis et al. 2013). Importantly, serum
levels of hsa-miR-1202 were reported to predict clinical
response to citalopram treatment of MDD patients (Lopez
et al. 2014b).
Two studies focused on microRNA levels as potential
biomarkers of MDD. In a candidate-driven approach, levels
of BDNF-regulating hsa-miR-132-3p and hsa-miR-182-5p
were increased in MDD, corresponding to decreased BDNF
levels and clinical symptomatology (Li et al. 2013b).
Mmu-miR-132-3p was previously identified to regulate
MeCP2 translation, thereby indirectly regulating BDNF in
mice (Klein et al. 2007). Recently, using microarrays,
mRNA and microRNA expression was studied in fibro-
blasts, and a distinct panel of 38 microRNAs associated
with altered gene expression in predicted targets related to
cell-to-cell communication, innate/adaptive immunity and
cell proliferation was reported (Garbett et al. 2014).
More studies have focused on changes of microRNA
expression along with antidepressant treatment in human
tissues. Initial investigations were reported in U87 MG
primary human glioblastoma-astrocytoma cell lines, incu-
bated with 7 lmol/l paroxetine (dissolved in DMSO).
Increased BDNF expression and its transcriptionally
inhibiting microRNA hsa-miR-30a-5p was observed within
6–12 h, however, these experiments were not controlled for
dissolving paroxetine in DMSO and may thus represent an
epiphenomenon (Angelucci et al. 2011). In a naturalistic
design, microRNA and mRNA expression were assessed in
peripheral mononuclear blood cells in a French case–con-
trol sample. Two microRNAs (hsa-miR-589-5p and hsa-
miR-941) were consistently upregulated in MDD patients
during the entire course of the study, while treatment
response was not predicted by up- or downregulation of
any microRNA investigated. The small sample size of 16
patients and 13 controls renders these findings to be con-
sidered preliminary (Belzeaux et al. 2012). Another study
focused on changes of microRNA and mRNA expression
upon paroxetine treatment of cultured lymphoblastoid cells
of healthy donors of Ashkenazi Jewish ancestry to identify
possible predictors of treatment response as modelled by
cell lines showing an inhibition of growth in response to
paroxetine. In female donors, an upregulation of hsa-miR-
151a-3p along with downregulation of its predicted, but not
experimentally confirmed, target CHL1 (Oved et al. 2012)
was reported. In male donors, downregulation of hsa-miR-
221-3p and hsa-miR-222-3p and upregulation of their
predicted, but not experimentally confirmed target ITGB3
was observed (Oved et al. 2013). In a small study inves-
tigating peripheral blood microRNA levels in 10 previ-
ously untreated Italian patients with MDD over 12 weeks
of treatment with escitalopram, 30 microRNAs were
reported to be dysregulated upon treatment, with most of
those microRNAs related to brain function in a pathway
analysis (Bocchio-Chiavetto et al. 2013). While these
results are hypothesis generating, a potential application of
microRNAs as biomarkers of MDD and treatment response
warrants further studies.
Anxiety disorders and related traits
Genetic studies
Only some studies focused on microRNAs in anxiety. The
majority of studies has been conducted in translational
models of murine anxiety-like behavior, which has been
reviewed in detail elsewhere (Malan-Müller et al. 2013).
The most comprehensive study in humans evaluated 712
SNPs in three case–control samples of Spanish, Estonian
and Finnish patients with panic disorder. SNPs in
MIR22HG (rs6502892) and MIR339 (rs11763020) were
reported to be nominally associated with panic disorder
with and without agoraphobia. Functional analysis of hsa-
miR-22-3p suggested regulation of anxiety disorder can-
didate gene expression such as BDNF, HTR2C, MAOA and
RGS2 (Muiños-Gimeno et al. 2011). Previously, the same
group had investigated the NTRK3 gene due to its sug-
gested role in neuronal plasticity and reported association
of a SNP in the 50 UTR with panic disorder (Armengol
et al. 2002). In obsessive–compulsive disorder, a SNP
(rs28521337) in the 30UTR of the NTRK3 was found to be
involved in binding of hsa-miR-485-3p and to be associ-
ated with the hoarding phenotype (Muiños-Gimeno et al.
2009).
Recently, rs41305272 in MAP2K5, modulating transla-
tional repression by hsa-miR-330-3p, was reported to be
associated with panic disorder with and without agora-
phobia and depression in a combined European–American
and African–American case–control sample of patients
suffering from comorbid substance or alcohol abuse (Jen-
sen et al. 2014).
In a different approach, genetic variation in 13 genes
previously reported to be differentially expressed between
non-anxious and anxious inbred mouse strains was tested
for association with anxiety disorders in a Finnish case–
control sample. An association of rs817782, located in the
30UTR of ALAD, with social phobia was reported (Donner
et al. 2008). This SNP is predicted to create a binding site
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for hsa-miR-204-5p and hsa-miR-211-5p by PolymiRTS
(Bhattacharya et al. 2014), although with a very low score.
Experimental validation of microRNA binding was not
conducted.
A recent study reported a SNP in the 30UTR of ACHE
(rs17228616) to modulate regulation of ACHE expression
by hsa-miR-608 (Hanin et al. 2014), pointing towards a
relevant fine tuning of the parasympathetic nervous system.
Carriers of the minor allele showed reduced cortisol levels
and elevated blood pressure, possible risk factors for anx-
iety and hypertension. Moreover, increased ACHE
expression was reported for homozygous minor allele
carriers in postmortem brain samples. However, whether
these findings suggest a clinical relevant risk for anxiety
disorders needs to be further explored by directly testing
categorical or dimensional anxiety phenotypes in case–
control samples.
A SNP (rs13212041) in the putative 30UTR of the sero-
tonin receptor HTR1B was reported to interfere with hsa-
miR-96-5p-mediated repression of gene expression and was
found to be associated with aggression, conduct disorder
behavior (Jensen et al. 2009) as well as with self-reported
anger and hostility in men, but not in women (Conner et al.
2010). The same SNP was also associated with trait
impulsivity (Varga et al. 2012). These results correspond to
a hyperaggressive behavior (Saudou et al. 1994) and
impaired impulse control (Bouwknecht et al. 2001) of mice
lacking 5-HT1B receptors. Recent reports suggest an adap-
tive regulatory role for mir-96 in rats not becoming helpless
during an inescapeable shock paradigm (Smalheiser et al.
2011). In a broader context, MIR96 is located with MIR182
and MIR183 in a 10 kb cluster on chromosome 7. Two SNPs
(rs2402959 and rs6965643) within 5 kb upstream of the
cluster were reported to be associated with attention deficit
hyperactivity disorder (ADHD) in a Spanish sample (Sán-
chez-Mora et al. 2013). However, some limitations con-
cerning the functional role of miR-96 must be considered.
Expression of miR-96 was predominantly found in sensory
structures but not brain tissue, and functional variants of
MIR96 were reported to cause progressive hearing loss in
mice and humans, but not behavioral changes (Mencı́a et al.
2009; Lewis et al. 2009). However, hsa-miR-1271-5p was
reported to be a brain expressed, non-conserved microRNA
sharing the seed sequence of hsa-miR-96-5p and thus also
repressing HTR1B (Jensen and Covault 2011). Moreover,
only the microRNA response element and not the complete
30UTR of HTR1B were tested in luciferase reporter assays
and, as of October 2014, rs13212041 is not any longer
localized within the currently annotated 30UTR of HTR1B.
Further molecular studies will enhance our understanding of
these microRNAs.
Concerning aggressive behavior, a SNP (rs1046322) in
WFS1 was reported to interfere with hsa-miR-668-3p
targeting and to be associated with self-reported aggression
in healthy probands (Kovacs-Nagy et al. 2013). WFS1 was
chosen due to behavioral abnormalities reported for the
Wolfram Syndrome (which is mediated by rare mutations in
WFS1) and translational data on behavior of Wfs1 deletion
mouse models. A second study by the same group identified
two SNPs in the 30UTR of SNAP-25 (rs3746544 and
rs1051312), previously reported to be associated with
ADHD (Kim et al. 2007), to interfere with binding and
repression of SNAP-25 expression by hsa-miR-641 and to be
associated with impulsivity (Németh et al. 2013). Presently,
no molecular or translational study on the role of these two
microRNAs concerning neuronal function is available.
Expression studies
No microRNA expression studies have been conducted for
anxiety disorders and related traits. An increase in whole
blood microRNA levels during and after a stressful con-
dition (academic examination) was reported in healthy
probands (Katsuura et al. 2012; Honda et al. 2013), with
hsa-miR-144-5p being significantly dysregulated in both
samples. Mir-144 was suggested to relate to cytokine
function. Moreover, a nominal significant dysregulation
was reported for hsa-miR-16-5p, a microRNA implicated
in regulating expression of the serotonin transporter
SLC6A4 in mice and humans (Moya et al. 2013) and to be
decreased upon chronic selective serotonin reuptake
inhibitor administration in mice (Baudry et al. 2010).
Discussion
Clinical studies have assessed heterogeneity and individu-
ality of mental disorders induced by microRNAs on the
level of genetic variation in microRNA genes, microRNA-
binding sites as well as genes related to microRNA pro-
cessing and on the level of microRNA expression in
postmortem brain samples as well as peripheral tissue. The
strength of genetic studies is to assess the risk induced by a
variant towards a disorder or a certain psychopathological
phenotype, whereas expression studies aim to identify
dysregulation of gene expression in a disorder, giving
direct evidence for involvement of a certain microRNA or
leading to biomarkers of diagnosis or treatment success.
We have focused the review on clinical studies conducted
in humans or with human tissue for two reasons: (I) Any
translational study is only an approximation towards the
divergent clinical aspects of human disorders, and (II)
microRNAs and their binding sites are less well conserved
than proteins, allowing only limited conclusions on heter-
ogeneity and individuality of human mental disorders in
the absence of direct human evidence.
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Studies have mainly focused on schizophrenia, puta-
tively promoted by the finding of rs1625579 in MIR137HG
as a genome-wide risk variant for SCZ. In conclusion,
genetic evidence points towards a rather modest impact of
microRNAs on phenotypic variance in SCZ, and some
reports are presently conflicting, e.g. concerning modula-
tion of SCZ symptoms, or brain activation patterns and
brain volume. While molecular characterization of miR-
137 has been undertaken, there is no research on MIR2682,
the second and human-specific microRNA located in
MIR137HG. It will be interesting to see, whether miR-2682
is also involved in synaptic plasticity and development.
Data on polymorphic microRNA-binding sites as well as
SNPs in microRNA processing genes have been reported,
but replications studies are rare and more specific investi-
gations are needed. For instance, it is known, that deletion
of 22q11.2, predisposing for SCZ, involves DGCR8 and
MIR185, yet both were not among the top hits in GWAS
data, thus future research is needed.
Concerning bipolar disorder and major depressive dis-
order, GWAS data and a cross-disorder analysis did not
specifically report variants related to microRNAs for BPD
and MDD. Although microRNAs were located in top-
regions of these studies, apart from MIR30E in MDD,
replication studies or large-scale microRNA-specific
investigations have not been reported. This raises the
possibility, that microRNAs exert small effects on indi-
vidual risk in these disorders, but studies may not have
been adequately powered due to specific statistical issues,
e.g. in MDD (Flint and Kendler 2014).
Independent of mental disorder, more data on dimen-
sional or intermediate phenotypes, which have been pro-
posed to reflect the underlying genetic risk factors of
mental disorders more adequately, would be very helpful to
complete the picture. In anxiety disorders, several neuro-
psychological traits such as behavioral inhibition or anxiety
sensitivity as well as a variety of neurobiological markers
(e.g. peripheral sympathetic activity, carbon dioxide reac-
tivity, response to cholecystokinin (CCK) challenge, startle
reflex) have been suggested as valid intermediate pheno-
types (for review see Domschke and Deckert 2012). Par-
ticularly neural activation correlates of emotional
processing as captured by functional magnetic resonance
imaging (fMRI) have been proposed as an intermediate
phenotype of anxiety as well as affective disorders viable
to genetic and therefore also future microRNA analyses
applying an imaging genetic approach (Domschke and
Dannlowski 2010). Comparable concepts also apply for
SCZ, BPD and MDD, with imaging genetics thus providing
promising additional information on microRNAs in mental
disorders (Meyer-Lindenberg and Weinberger 2006), yet
statistical analysis makes large sample size for adequate
power mandatory (Bowman 2014).
However, the genetic approach has limitations, e.g.
cases and controls need to be properly matched regarding
ethnicity or gender, deviation of control samples from
Hardy–Weinberg equilibrium may confound the results and
genetic association studies do not assess the risk by de
novo and ultra-rare mutations, which may be overcome by
next-generation sequencing data. It may also be conceiv-
able, that a polymorphism has a protective role during
development, but may predispose to disorders at later time
points and vice versa. On a more general level, identified
genetic variation of microRNAs may affect their expres-
sion, maturation and processing, but experimental valida-
tion is necessary to assess, whether a polymorphism has a
functional role at all. Moreover, human evidence suggests
that individual genetic variance is rather small for micr-
oRNA genes, given their importance in numerous regula-
tory pathways (Han and Zheng 2013). Putatively,
interference of microRNAs at more redundant points of
biological pathways, e.g. mutations in 30UTR microRNA-
binding sites, may therefore be more important. However,
in most instances it is still an open question whether an
identified regulation of a target gene by a microRNA is
biologically relevant. How to detect small short-term and
long-term effects of functionally relevant microRNA
polymorphisms in cellular signaling networks may thus be
of great scientific importance for our biological under-
standing of mental disorders.
It should be mentioned, that other non-coding RNA
molecules may be involved in neuronal processes puta-
tively related to mental disorders. Long non-coding RNA
molecules may counteract microRNA action by scavenging
microRNAs or compete at microRNA-binding sites (Barry
2014). As a consequence, positive or negative regulation of
microRNA signaling may be mediated independent of
genetic variation or altered microRNA levels.
Expression studies of microRNAs are even more diffi-
cult to interpret. While in other disorders, e.g. heart failure
(Thum et al. 2007) a considerably larger dysregulation of
specific microRNAs was reported, most microRNAs were
observed to be dysregulated within a factor of two in
mental disorders. Several limitations need to be considered.
Expression patterns of microRNAs differ in various brain
regions, are cell-type specific, and may thus derive from a
change on the cell types present, e.g. due to gliosis or
invasion by microglia (Smalheiser et al. 2014). Limiting
analysis to synaptosome or exosomes may give more
selective information (Lugli et al. 2012). The impact of the
agony process on neuronal microRNA expression is cur-
rently not fully known, yet hypoxia- and anoxia-stress are
known to change microRNA expression and may thus be
physiological confounders (Kulshreshtha et al. 2007; Peng
et al. 2011). Concerning peripheral tissues and blood cell
lines, viral load, energy level, growth rate, sex and age are
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known to influence results (Sanders et al. 2013). Moreover,
technical issues may also need to be considered. High-
throughput quantitative real-time PCRs often do not apply
same-sample technical replicates as well as dilution rows,
making it more difficult to assess technical issues of the
investigated sample. The methods of analyzing sequencing
data and normalization of microRNA expression to a ref-
erence microRNA are important confounders, affecting
both real-time PCR based as well as next-generation
sequencing data (Kohen et al. 2014). For instance, micr-
oRNA expression in postmortem prefrontal cortex sug-
gested canonical reference RNAs U6, U44 and U48 and
their geometric mean to be not equally distributed and
balanced across the investigated diagnostic groups
(Smalheiser et al. 2014). A second layer of limitations
results from methodological issues of (high-throughput)
quantitative real-time PCR. It would be very helpful, if all
studies provide raw Ct values along with standard devia-
tion for all tested microRNAs. An interesting insight allows
the supplement of a recent study assessing peripheral blood
mononuclear cell (PBMC) microRNA expression in MDD
(Belzeaux et al. 2012): the two microRNAs showing a
dysregulation in PBMCs over the complete time course of
the study had a mean Ct value of 32.25 ± 1.83 (hsa-miR-
941) and 32.86 ± 1.84 (hsa-miR-589) across all cases and
controls. This is very close to the authors’ cutoff for
background, represented by Ct values above 33, like many
dysregulated microRNAs exhibit very low expression.
In light of these limitations, translational research pro-
vides a valuable second line of evidence. Data from murine
models of depression-like and anxiety-like traits presently
complement human studies to a large extent. As the focus
of the review is on presently available human evidence, we
would like to refer the reader to excellent reviews by others
for a more general perspective of this topic (Mouillet-
Richard et al. 2012; Hansen and Obrietan 2013; Dwivedi
2014). Main foci of microRNA-related translational
research on major depression and suicidal behavior have
been neurogenesis and neuroplasticity, BDNF-signaling,
stress-induced neuronal adaptations, as well as the action of
antidepressants (Serafini et al. 2012). Mir-16 was suggested
to be induced by administration of selective serotonin re-
uptake inhibitors (Baudry et al. 2010). Putatively, the
action of mood stabilizers may also involve miR-16, as
well as miR-15, by repressing BCL2 (Cimmino et al. 2005),
and lithium was reported to increase BCL2 levels (for
review see Marmol 2008). However, direct experimental
evidence is missing and an increase, rather than a decrease
in miR-15a was reported upon valproate administration in
rat hippocampus (Zhou et al. 2009). More recently, miR-
135 was reported to repress expression of the serotonin
transporter and the serotonin 5-HT1A-receptor, and to
increase upon chronic imipramine administration in mice
(Issler et al. 2014). These studies are very important for
understanding basic molecular processes and identifying
novel molecular mechanism, which help understanding
current therapeutic options and may allow development of
future therapeutic approaches. Local regulation of protein
synthesis at synapses may be important in learning. CREB-
BDNF pathways may exhibit important roles in regulating
the homeostasis of neural pathways by microRNAs, and
thus represent another interesting novel pharmaceutical
target (Serafini et al. 2012). However, contrary to proteins,
microRNAs and their binding sites are less conserved than
proteins, emphasizing the necessity of reciprocal human
and clinical validation of translational research.
Finally and relating to all types of studies, the ratio of
the number of patients to the number of microRNAs ana-
lyzed is often rather small, seriously raising the possibility
of false-positive discoveries and making independent (not
same-team or same-sample) validation mandatory (Ioan-
nidis 2005). Even then, current pathway analysis of mi-
croRNAs suffers from the high false-positive rate of
microRNA:mRNA interaction prediction, thus reflecting
the need of experimental validation.
Conclusion
Although microRNAs are known for more than 20 years,
our understanding of their functional roles is still evolving
and research on mental disorders has just recently turned
on them. The rapidly increasing number of annotated mi-
croRNAs has opened a large field of possible interactions,
which may be important in pathology, but may also be
applied to novel pharmacological approaches. Concerning
disease mechanisms and new pharmacological approaches,
translational research is promising, but issues of conser-
vation of microRNA biology across species may be a rel-
evant limitation. It will thus be an important field of
research to identify the molecular roles for human-specific
microRNAs in neural tissues. Recent methodological
advances may greatly accelerate the identification of
microRNA-binding sites in the human brain (Boudreau
et al. 2014).
Genetic studies directly assess the contribution of
known genetic variants to heterogeneity in terms of dis-
order risk and individuality in terms of phenotypic vari-
ance. As such, the encouraging results on MIR137HG and
its SNP rs1625579 in schizophrenia represent paradigmatic
research, which should be applied to all mental disorders.
However, data also point out, that only large studies can
really assess the importance and relevance of microRNAs
in mental disorders (Kendler 2013). Once more results
have been replicated in adequately powered samples, e.g.
by GWAS or meta-analyses as well as functional
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investigations such as fMRI, we will almost certainly be
able to better understand the individuality of our patients
due to genetic variation in microRNAs.
Expression studies are presently in an early stage and
often limited by technical issues and a lack of replication.
Once the methods of microRNA extraction, detection and
normalization have been reliably standardized, it will be
interesting to see, whether microRNAs can really help as
biomarkers of disorder or treatment response to better
understand the individuality of our patients and develop
individualized therapeutic approaches.
Based on our present knowledge, microRNAs thus add
an increasingly complex layer of heterogeneity and indi-
viduality to mental disorders and might give rise to more
differentiated and individualized therapeutic approaches in
the future.
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